
PRESS RELEASE

LATTICE MEDICAL announces the closing of a €8 million Series A financing round

Lille, October 1, 2022 - **LATTICE MEDICAL**, announces the closing of a second round of financing of **8 million euros**. This round was led by the historical funds **Finovam Gestion**, **Nord France Amorçage** and **WISEED** alongside the **Capttech Santé** fund. The **European Commission**, via its **EIC Fund**, and **Santelys** are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt from **BPIFrance** and the **EIC accelerator**.

On the way to clinical trials

The first objective of this financing round is the completion of the pre-market clinical evaluation of the MATTISSE implant. The clinical trial, started in July 2022 and plans to recruit 50 patients eligible for immediate breast reconstruction in 8 centers in Europe. This clinical trial will last 36 months and will lead to CE marking. This clinical investigation called TIDE, had a first successful implantation by 12th of July at the Institute of Clinical Oncology with a 63 years old patient operated with MATTISSE in the case of her breast cancer and immediate reconstruction.

CE marking, industrialisation and hiring for the marketing of MATTISSE

The second objective of this fundraising is to obtain the CE mark and to start sales of the MATTISSE implant. For this, LATTICE MEDICAL plans to hire a dozen people between now and 2024, particularly in production, marketing, communication and sales. The fundraising will also allow to upgrade and expand the current pilot production equipment set up by the company 2 years, ahead of the commercial launch.

Consolidate R&D efforts and the development of new products

In order to sustain its investments and production equipment, LATTICE MEDICAL is consolidating its R&D effort and developing other healthcare products using 3D printing for tissue reconstruction. In particular, the implantable medical device RODIN is being developed, capable of repairing deep skin lesions, common among soldiers, linked to trauma caused by explosions or firearms for example. Through its brand LATTICE SERVICES, we reinforce the marketing of our medical filaments for 3D printing.



FINOVAM
GESTION

WiSEED
CONNECT. INVEST. COLLECT.

NFA
NORD FRANCE AMORÇAGE



European
Innovation
Council
Fund



bpifrance


LATTICE MEDICAL
Soft Tissue Reconstruction

LATTICE MEDICAL is an implantable medical device company that develops and manufactures a breakthrough resorbable implant supporting reconstruction with one's own body fat (" autologous fat reconstruction"). The company has about 20 employees and a 3D printing production site dedicated to implantable medical devices.

The first application of its technology is for breast reconstruction after cancer. Currently, one out of woman gets sooner or later breast cancer. In 40% of cases, the treatment is surgical with a complete or partial mastectomy. The current reconstruction techniques (breast implants or autologous surgical techniques) require cumbersome, multiple, costly surgical procedures so that only 14% of women get a reconstruction. LATTICE MEDICAL's medical implant "MATTISSE" has the potential to change this radically. It allows the regeneration of autologous fatty tissue and is completely resorbed by the body after breast reconstruction, thus avoiding additional surgeries and long-term consequences and risks for patients.

CAPTECH SANTE: is an early-stage investment fund in Biotechnology, Medical Devices, Digital Health and Nutrition. Captech Santé is managed by a dedicated team of experts in the life sciences. The fund brings to its participations its important network in the industrial and technological fields. The fund is managed by Finorpa Gestion, a management company based in Lille, with 30 years of experience in investment. Created in November 2021, CAPTECH SANTE is making its 6th investment with the company Lattice Medical.

www.finorpa.fr

FINOVAM GESTION: An AMF-approved management company, FINOVAM GESTION supports entrepreneurs from the early stages of their project and throughout their subsequent development in five key sectors: Digital, Health and Biotechnology, Bioeconomy, Energy Transition and Industry of the Future. With a recognized experience in venture capital, the management team is spread over four sites (Lille, Amiens, Metz and Dijon) and puts its expertise and its network at the service of innovative companies in the three regions of Hauts-de-France, Grand Est and Bourgogne Franche-Comté. FINOVAM Gestion manages four investment funds for a total amount under management of €100M and a portfolio of 60 innovative companies.

www.finovamgestion.fr Hélène Cannard hcannard@finovamgestion.fr

NFA: Created in 2013, Nord France Amorçage is a €36M co-investment fund wholly owned by the Hauts-de-France Region with the support of Europe and managed by the Siparex Group. Dedicated to financing innovative companies that create jobs and added value for the region, Nord France Amorçage has invested more than €32 million in 90 companies in all sectors. NFA has co-invested with FINOVAM GESTION and WiSEED in the first round of financing of LATTICE MEDICAL. Guillaume Bruniaux represents the investment fund on the company's board. <http://www.nord-france-amorçage.fr/>

WiSEED: WiSEED is the first equity crowdfunding platform that allows individuals to invest from 100 EUR in the capital of companies. The WiSEED community trusted LATTICE MEDICAL by participating in its first round of financing alongside FINOVAM GESTION and NFA. François Martin represents the investment fund on the company's board.

<https://www.wiseed.com/fr>



LATTICE MEDICAL
70 rue du Docteur Yersin
59120 LOOS -France
<https://www.lattice-medical.com>
contact@lattice-medical.com
Phone: +33.09.73.79.84.12



FINOVAM
GESTION

WISEED
CONNECT. INVEST. COLLECT.

NFA
NORD FRANCE AMORÇAGE



European
Innovation
Council
Fund



bpifrance


LATTICE MEDICAL
Soft Tissue Reconstruction

SANTELYS :Santély is an establishment specialised in health and home care and in the field of training. Santély provides home hospitalization or the dispensation of care or services that allow for comprehensive patient care, regardless of age, level of dependence and their state of health. Santély pursues its commitment to the public interest by supporting and accompanying research and innovation in healthcare in order to experiment and propose innovative care solutions for the benefit of patients and healthcare professionals. <https://www.santelys.asso.fr>

EIC FUND:

The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance.

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

3

BPIFRANCE: Bpifrance finances companies - at every stage of their development - with credit, guarantees and equity. Bpifrance supports them in their innovation and international projects. Bpifrance now also proposes their export activity through a wide range of products. Consulting, university, networking and acceleration programs for startups, SMEs and Large Companies are also part of the offer proposed to entrepreneurs. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single and efficient contact to help them face their challenges. Marie-Laurence Descamps, health business manager at BPIFrance Lille, is LATTICE MEDICAL's main contact. www.Bpifrance.fr - <https://presse.bpifrance.fr/>